Verseon Presents Two Precision Oral Anticoagulants with Low Bleeding at International Stroke Conference
Millions of patients worldwide could benefit from safe, long-term therapy combining an oral anticoagulant with one or more antiplatelet drugs (i.e. aspirin, PlavixTM) to prevent stroke or heart attack. With current anticoagulants, however, such combination treatment is generally limited to 12 months because of an increased risk of major bleeding. Verseon’s PROACs have demonstrated low bleeding and sparing of platelet function in preclinical testing, making them promising candidate for this large group of patients.
In contrast to conventional pharma companies that typically rely on a single compound per drug program, Verseon’s drug development platform allows them to systematically generate multiple chemically distinct drug candidates for each disease area. As a result, the company is currently conducting a phase 1 trial on the lead PROAC VE-1902 and expects to also advance a second PROAC, VE-2851, into clinical trials.
“Our drug discovery process is a confluence of physics, chemistry, biology, and high-performance computing that is needed to efficiently design new compounds out of reach by conventional methods,” said Adityo Prakash, CEO of Verseon. “The PROACs are excellent examples of how our approach brings multiple therapeutic candidates forward for addressing large, unmet medical needs.”
Verseon’s computational platform is built on advanced physics-based modeling, novel optimization algorithms, and a proprietary chemistry knowledge base. These computational engines are integrated into highly efficient, purpose-built chemistry and biology laboratory workflows. This unique approach distinguishes Verseon from traditional modes of pharmaceutical development and allows them to identify on the computer novel small molecules that bind to the disease-causing target protein. In this way, the company synthesizes only the most promising compounds for laboratory evaluation and clinical trials.
About Verseon’s PROACs
Verseon’s PRrecision Oral AntiCoagulants (PROACs) have shown excellent efficacy in multiple preclinical studies without disruption of platelet function. This unique feature could explain the low bleeding of the PROACs observed in preclinical testing, making PROACs excellent candidates for use in long-term combination anticoagulant-antiplatelet therapy. Lead PROAC VE-1902, which is currently in a phase I clinical trial, was well-tolerated in regulatory toxicity studies and demonstrated low renal clearance, a desirable property for patients with impaired kidney function. Verseon is also advancing a second PROAC, VE-2851, for clinical trials.
Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform paired with a comprehensive in-house chemistry and biology workflow to build a growing drug development pipeline. The company is applying its platform to a growing drug pipeline and currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Verseon Corporation—Tina Schlafly
+1 510 225 9014
Vane Percy & Roberts—Simon Vane Percy
+44 (0) 1737 821 890